NO932672L - MONOCLOAN ANTIBODIES AGAINST ELAM-1 AND APPLICATIONS THEREOF - Google Patents

MONOCLOAN ANTIBODIES AGAINST ELAM-1 AND APPLICATIONS THEREOF

Info

Publication number
NO932672L
NO932672L NO93932672A NO932672A NO932672L NO 932672 L NO932672 L NO 932672L NO 93932672 A NO93932672 A NO 93932672A NO 932672 A NO932672 A NO 932672A NO 932672 L NO932672 L NO 932672L
Authority
NO
Norway
Prior art keywords
elam
monocloan
applications
antibodies against
against elam
Prior art date
Application number
NO93932672A
Other languages
Norwegian (no)
Other versions
NO932672D0 (en
Inventor
Elisabeth Wayner
Mary L Phillips
Jeffrey L Winkelhake
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of NO932672D0 publication Critical patent/NO932672D0/en
Publication of NO932672L publication Critical patent/NO932672L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Blandinger og fremgangsmåter er tilveiebragt for inhiber- ing av inflammatoriske og andre sykdomsresponser formidlet av ELAM-1. Spesielt tilveiebringer den foreliggende oppfinnelse immunglobuliner som selektivt binder funksjonelle epitoper på ELAM-1 og blokkerer tilhefting av leukocytter til aktiverte endotelceller både in vitro og in vivo.Compositions and methods are provided for inhibiting inflammatory and other disease responses mediated by ELAM-1. In particular, the present invention provides immunoglobulins that selectively bind functional epitopes on ELAM-1 and block adhesion of leukocytes to activated endothelial cells both in vitro and in vivo.

NO93932672A 1991-01-24 1993-07-23 MONOCLOAN ANTIBODIES AGAINST ELAM-1 AND APPLICATIONS THEREOF NO932672L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64587891A 1991-01-24 1991-01-24
US73303391A 1991-07-22 1991-07-22
PCT/US1992/000577 WO1992012729A1 (en) 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses

Publications (2)

Publication Number Publication Date
NO932672D0 NO932672D0 (en) 1993-07-23
NO932672L true NO932672L (en) 1993-09-23

Family

ID=27094802

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93932672A NO932672L (en) 1991-01-24 1993-07-23 MONOCLOAN ANTIBODIES AGAINST ELAM-1 AND APPLICATIONS THEREOF

Country Status (11)

Country Link
EP (1) EP0568631A4 (en)
JP (1) JPH06505253A (en)
AU (1) AU1269092A (en)
CA (1) CA2100681A1 (en)
IE (1) IE920206A1 (en)
IL (1) IL100764A0 (en)
NO (1) NO932672L (en)
NZ (1) NZ241399A (en)
OA (1) OA09809A (en)
SK (1) SK77393A3 (en)
WO (1) WO1992012729A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
WO1996040942A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Humanized antibodies to e-selectin
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2010098788A2 (en) * 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD FOR PREDICTING AND EVALUATING A THERAPEUTIC EFFECT IN DISEASES ASSOCIATED WITH IL-6 AND NEUTROPHILS
EP3698808B1 (en) * 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (en) 2018-01-31 2019-08-08 元一 加藤 Therapeutic agent for asthma containing il-6 inhibitor
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
JP7449390B2 (en) 2020-01-24 2024-03-13 ファイザー・インク Anti-E-selectin antibodies, compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
ATE142505T1 (en) * 1988-11-14 1996-09-15 Brigham & Womens Hospital ANTIBODIES SPECIFIC TO ELAM-1 AND THEIR USE
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Also Published As

Publication number Publication date
NO932672D0 (en) 1993-07-23
IL100764A0 (en) 1992-09-06
SK77393A3 (en) 1994-12-07
NZ241399A (en) 1994-06-27
IE920206A1 (en) 1992-07-29
CA2100681A1 (en) 1992-07-25
JPH06505253A (en) 1994-06-16
EP0568631A4 (en) 1995-04-05
WO1992012729A1 (en) 1992-08-06
OA09809A (en) 1994-04-15
EP0568631A1 (en) 1993-11-10
AU1269092A (en) 1992-08-27

Similar Documents

Publication Publication Date Title
NO932672L (en) MONOCLOAN ANTIBODIES AGAINST ELAM-1 AND APPLICATIONS THEREOF
DE69531679D1 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
DK297184A (en) IMMUNOTOXIN CONJUGATES FOR SELECTIVE ELIMINATION OF CELL POPULATIONS
NO961151D0 (en) Antibodies to CD40
DK0673255T3 (en) Monoclonal antibodies that specifically bind to vascular tumor endothelium and applications thereof
WO2020041541A3 (en) Anti-tigit antibodies
NO924088L (en) ANTIBODIES, PROCEDURES FOR THEIR PREPARATION AND APPLICATION OF THEM
DE69637890D1 (en) MONOCLONAL ANTIBODY FOR THE INHIBITION OF HIV-1-HÜLLGYKOPROTEIN-MEDIATED MEMBRANE FUSION
BR9508985A (en) Retinoic acid x receptor binders
NO20071717L (en) Anti-Fc gamma RIIB receptor antibody and its applications
ATE412432T1 (en) INTERNALIZING ERBB2 ANTIBODIES
NO20053389D0 (en) Antibodies against PD-1 and their applications.
DE60226486D1 (en) SELF-ARRANGING MOLECULES
DE69227456D1 (en) PROOF OF COLLAGEN DEGRADATION -I (IN VIVO)
EP0728215A4 (en) METHOD FOR BINDING AN ELEMENT TO THE PEPTIDE -g (b) -AMYLO DE
DK1242115T3 (en) Chemically programmable immunity
DE69737683D1 (en) ANTIBODIES TO THE ED-B DOMAIN OF FIBRONECTIN, THEIR PREPARATION AND USES
EA200401198A1 (en) ANTIBODIES AGAINST αvβ6
NO20021686D0 (en) Methods for Preparation of Target Molecules in a Transgenic Animal and Purification of the Target Molecule
DK1003552T3 (en) LO-CD2a antibody and its uses for inhibiting T cell activation and proliferation
NO20010747D0 (en) Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
EP0350690A3 (en) Neutralisation of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and by fragments derived therefrom
WO2021263167A3 (en) Il-10 muteins and fusion proteins thereof
DK0802924T3 (en) Drug for Prolonged Immunosuppression and Elimination of Tumor Cells
YU85501A (en) A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders